Sign In

Login

Password

Forgot Password ? Sign Up

ダパグリフロジン (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "ダパグリフロジン" in Japanese language version.

refsWebsite
Global rank Japanese rank
8nih.gov
4th place
24th place
6doi.org
2nd place
6th place
1astrazeneca.co.jp
low place
low place
1jiho.jp
low place
3,872nd place
1m3.com
low place
2,027th place
1pmda.go.jp
6,690th place
394th place
1fda.gov
447th place
1,043rd place
1nikkeibp.co.jp
1,415th place
95th place

astrazeneca.co.jp

doi.org

  • Yang, Li; Li, Haiyan; Li, Hongmei; Bui, Anh; Chang, Ming; Liu, Xiaoni; Kasichayanula, Sreeneeranj; Griffen, Steven C. et al. (2013). “Pharmacokinetic and Pharmacodynamic Properties of Single- and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects”. Clinical Therapeutics 35 (8): 1211–1222.e2. doi:10.1016/J.Clinthera.2013.06.017. PMID 23910664. 
  • Plosker, Greg L. (2012). “Dapagliflozin”. Drugs 72 (17): 2289–2312. doi:10.2165/11209910-000000000-00000. PMID 23170914. 
  • “Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial”. J Am Coll Cardiol. 83 (20): 1973-1986.. (May 2024). doi:10.1016/j.jacc.2024.03.385.. PMID 38537918. 
  • “Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure.”. J Am Coll Cardiol. 83 (14): 1295-1306.. (April 2024). doi:10.1016/j.jacc.2024.02.009.. PMID 38569758. 
  • Bhartia, Mithun; Tahrani, Abd A.; Barnett, Anthony H. (2011). “SGLT-2 Inhibitors in Development for Type 2 Diabetes Treatment”. The Review of Diabetic Studies 8 (3): 348–354. doi:10.1900/RDS.2011.8.348. PMC 3280669. PMID 22262072. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280669/. 
  • Yang, Li; Li, Haiyan; Li, Hongmei; Bui, Anh; Chang, Ming; Liu, Xiaoni; Kasichayanula, Sreeneeranj; Griffen, Steven C. et al. (2013). “Pharmacokinetic and Pharmacodynamic Properties of Single- and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects”. Clinical Therapeutics 35 (8): 1211–1222.e2. doi:10.1016/J.Clinthera.2013.06.017. PMID 23910664. 

fda.gov

jiho.jp

nk.jiho.jp

m3.com

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Yang, Li; Li, Haiyan; Li, Hongmei; Bui, Anh; Chang, Ming; Liu, Xiaoni; Kasichayanula, Sreeneeranj; Griffen, Steven C. et al. (2013). “Pharmacokinetic and Pharmacodynamic Properties of Single- and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects”. Clinical Therapeutics 35 (8): 1211–1222.e2. doi:10.1016/J.Clinthera.2013.06.017. PMID 23910664. 
  • Plosker, Greg L. (2012). “Dapagliflozin”. Drugs 72 (17): 2289–2312. doi:10.2165/11209910-000000000-00000. PMID 23170914. 
  • “Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial”. J Am Coll Cardiol. 83 (20): 1973-1986.. (May 2024). doi:10.1016/j.jacc.2024.03.385.. PMID 38537918. 
  • “Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure.”. J Am Coll Cardiol. 83 (14): 1295-1306.. (April 2024). doi:10.1016/j.jacc.2024.02.009.. PMID 38569758. 
  • Bhartia, Mithun; Tahrani, Abd A.; Barnett, Anthony H. (2011). “SGLT-2 Inhibitors in Development for Type 2 Diabetes Treatment”. The Review of Diabetic Studies 8 (3): 348–354. doi:10.1900/RDS.2011.8.348. PMC 3280669. PMID 22262072. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280669/. 
  • Yang, Li; Li, Haiyan; Li, Hongmei; Bui, Anh; Chang, Ming; Liu, Xiaoni; Kasichayanula, Sreeneeranj; Griffen, Steven C. et al. (2013). “Pharmacokinetic and Pharmacodynamic Properties of Single- and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects”. Clinical Therapeutics 35 (8): 1211–1222.e2. doi:10.1016/J.Clinthera.2013.06.017. PMID 23910664. 

ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

nikkeibp.co.jp

medical.nikkeibp.co.jp

pmda.go.jp

info.pmda.go.jp